Low-dose NOAC linked to lower bleeding rates vs triple therapy in patients with Afib having PCI

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • Patients with atrial fibrillation (Afib) having percutaneous coronary intervention have less clinically significant bleeding with low- or very-low-dose rivaroxaban combination therapies vs triple therapy with vitamin K antagonist.

Why this matters  

  • Usual therapy is vit...